Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRSP Stock Forecast 2026-2027
$51.84
Current Price
$5.08B
Market Cap
Buy 15
Hold 9
Sell 1
Wall St Analyst Ratings
Distance to CRSP Price Targets
+461.3%
To High Target of $291.00
+46.6%
To Median Target of $76.00
-36.3%
To Low Target of $33.00
CRSP Price Momentum
-4.3%
1 Week Change
-5.5%
1 Month Change
+23.8%
1 Year Change
-1.1%
Year-to-Date Change
-33.9%
From 52W High of $78.48
+40.0%
From 52W Low of $37.02
📊 TOP ANALYST CALLS
Did CRSP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CRISPR is one of their latest high-conviction picks.
Latest CRSP Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CRSP has a bullish consensus with a median price target of $76.00 (ranging from $33.00 to $291.00). The overall analyst rating is Buy (7.9/10). Currently trading at $51.84, the median forecast implies a 46.6% upside. This outlook is supported by 15 Buy, 9 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRSP Analyst Ratings
15
Buy
9
Hold
1
Sell
CRSP Price Target Range
Low
$33.00
Average
$76.00
High
$291.00
Current: $51.84
Latest CRSP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRSP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | Bernstein | William Pickering | Market Perform | Maintains | $56.00 |
| May 6, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $82.00 |
| Mar 17, 2026 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Feb 17, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Feb 13, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Feb 13, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Feb 13, 2026 | Needham | Buy | Maintains | $N/A | |
| Jan 30, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Dec 23, 2025 | Needham | Buy | Reiterates | $N/A | |
| Dec 23, 2025 | Citizens | Market Outperform | Reiterates | $N/A | |
| Nov 26, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 12, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Nov 11, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Nov 11, 2025 | Baird | Neutral | Maintains | $N/A | |
| Nov 10, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 17, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Oct 10, 2025 | Needham | Buy | Reiterates | $N/A | |
| Sep 23, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 18, 2025 | JP Morgan | Overweight | Initiates | $N/A | |
| Aug 7, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Crispr Therapeutics AG (CRSP) Competitors
The following stocks are similar to CRISPR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CRSP
CRISPR Therapeutics
mkt cap
5.00B
Crispr Therapeutics AG (CRSP) Financial Data
Crispr Therapeutics AG has a market capitalization of $5.08B with a P/E ratio of -8.0x. The company generates $4.10M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +68.6% quarter-over-quarter, while maintaining an operating margin of -8,933.3% and return on equity of -31.2%.
Valuation Metrics
Market Cap
$5.08B
Enterprise Value
$3.35B
P/E Ratio
-8.0x
PEG Ratio
0.4x
Price/Sales
1,244.3x
Growth & Margins
Revenue Growth (YoY)
+68.6%
Gross Margin
-4,494.9%
Operating Margin
-8,933.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+48.8%
Current Ratio
18.0x
Debt/Equity
43.4x
ROE
-31.2%
ROA
-14.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Crispr Therapeutics AG (CRSP) Business Model
About Crispr Therapeutics AG
What They Do
Develops gene editing-based medicines for serious diseases.
Business Model
The company generates revenue by developing and commercializing gene therapies using its proprietary CRISPR/Cas9 platform. It focuses on addressing serious medical conditions through a portfolio of approved and investigational therapies, collaborating with strategic partners in the biotech and life sciences sectors to enhance its development and commercialization efforts.
Additional Information
CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and is actively involved in addressing unmet medical needs across various therapeutic areas, including hemoglobin disorders, oncology, and rare diseases. Its innovative approach positions the company as a key player in the rapidly evolving gene editing market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
393
CEO
Dr. Samarth Kulkarni Ph.D.
Country
Switzerland
IPO Year
2016
Website
www.crisprtx.comCrispr Therapeutics AG (CRSP) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 03, 2026
By Zacks Equity Research
Realtime BLOG
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Jun 02, 2026
By Ekta Bagri
Genomics & Synthetic Biology
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
Jun 01, 2026
By Kinjel Shah
Analyst Blog
Latest News
Quick Summary
CRISPR Therapeutics AG (CRSP) presented at the 46th Annual William Blair Growth Stock Conference, sharing insights on its developments and growth strategies.
Why It Matters
CRISPR Therapeutics' presentation at a key investment conference highlights its growth potential and innovation, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
5 days ago
Quick Summary
CRISPR's Casgevy positions the company as a leader in gene-editing therapies, with expected commercial growth as it reaches more patients.
Why It Matters
CRISPR's leadership in gene editing and expanding patient access to Casgevy may drive revenue growth, enhancing market position and potential returns for investors.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
CRISPR Therapeutics (CRSP) reported earnings 30 days ago; investors should monitor upcoming developments for insights into the stock's future performance.
Why It Matters
CRISPR Therapeutics' recent earnings report may signal future performance trends, impacting stock valuation and investor sentiment based on growth prospects and market reactions.
Source: Zacks Investment Research
Market Sentiment:
Negative
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript
5 days ago
Quick Summary
CRISPR Therapeutics AG (CRSP) presented at the Jefferies Global Healthcare Conference, showcasing updates and developments in their biotechnology initiatives.
Why It Matters
CRISPR Therapeutics’ presentation at a major healthcare conference signals potential advancements in gene editing, which could impact stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CRISPR Therapeutics (CRSP) is gaining attention from Zacks.com users, indicating increased interest and potential developments for the stock in the near future.
Why It Matters
Increased attention from Zacks.com users may signal heightened interest and potential volatility in CRISPR Therapeutics' stock, impacting trading strategies and price movements.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eli Lilly reported positive results from a clinical trial for a gene-editing candidate, positioning it as a competitor to CRISPR Therapeutics in the biotech sector.
Why It Matters
Eli Lilly's positive trial results boost its competitive position in gene editing, potentially impacting market dynamics and valuations for biotech firms like CRISPR Therapeutics.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About CRSP Stock
What is Crispr Therapeutics AG's (CRSP) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Crispr Therapeutics AG (CRSP) has a median price target of $76.00. The highest price target is $291.00 and the lowest is $33.00.
Is CRSP stock a good investment in 2026?
According to current analyst ratings, CRSP has 15 Buy ratings, 9 Hold ratings, and 1 Sell ratings. The stock is currently trading at $51.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRSP stock?
Wall Street analysts predict CRSP stock could reach $76.00 in the next 12 months. This represents a 46.6% increase from the current price of $51.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Crispr Therapeutics AG's business model?
The company generates revenue by developing and commercializing gene therapies using its proprietary CRISPR/Cas9 platform. It focuses on addressing serious medical conditions through a portfolio of approved and investigational therapies, collaborating with strategic partners in the biotech and life sciences sectors to enhance its development and commercialization efforts.
What is the highest forecasted price for CRSP Crispr Therapeutics AG?
The highest price target for CRSP is $291.00 from at , which represents a 461.3% increase from the current price of $51.84.
What is the lowest forecasted price for CRSP Crispr Therapeutics AG?
The lowest price target for CRSP is $33.00 from at , which represents a -36.3% decrease from the current price of $51.84.
What is the overall CRSP consensus from analysts for Crispr Therapeutics AG?
The overall analyst consensus for CRSP is bullish. Out of 4 Wall Street analysts, 15 rate it as Buy, 9 as Hold, and 1 as Sell, with a median price target of $76.00.
How accurate are CRSP stock price projections?
Stock price projections, including those for Crispr Therapeutics AG, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 10:07 PM UTC